

Drug Policy

Policy: Corticosteroid Inhalers Preferred Step Therapy <ul style="list-style-type: none">• Alvesco	Annual Review Date: 02/15/2024 Last Revised Date: 02/15/2024
---	---

OVERVIEW

All of the corticosteroid inhalers are indicated for the **maintenance treatment of asthma**. Flovent (Diskus and HFA), Qvar RediHaler, and Asmanex Twisthaler 110 mg are approved for patients ≥ 4 years of age; Arnuity Ellipta 50 mcg0, and Asmanex HFA are approved for patients ≥ 5 years of age; Pulmicort Flexhaler is approved for patients ≥ 6 years of age; Alvesco ArmonAir Digihaler, Arnuity Ellipta 100 or 200 mcg, and Asmanex Twisthaler 220 mcg are approved for patients ≥ 12 years of age. None of the corticosteroid inhalers are indicated for the relief of acute bronchospasm.

POLICY STATEMENT

A preferred step therapy program has been developed to encourage the use of a preferred product prior to the use of a non-preferred product. If the preferred step therapy rule is not met for a non-preferred product at the point of service, coverage will be determined by the preferred step therapy criteria below.

Automation: A patient with a history of one Preferred Product within the 130-day look-back period is excluded from Step Therapy.

Preferred products:

- Arnuity Ellipta
- Asmanex HFA
- Asmanex Twisthaler
- Qvar RediHaler

Non-preferred products:

- Alvesco

CRITERIA

1. If the patient has tried one preferred product, then authorization for a non-preferred product may be given.

Approval: 365 days (1 year)

Step Therapy Exception Criteria

In certain situations, the patient is not required to trial preferred products. Approve for 1 year if the patient meets the following (A, B, or C):

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. <https://www.medmutual.com/For-Providers/Policies-and-Standards/Prescription-Drug-Resources.aspx>

Drug Policy

- A. The patient has an atypical diagnosis and/or unique patient characteristics which prevent use of all preferred products. If so, please list diagnosis and/or patient characteristics [documentation required]; **OR**
- B. The patient has a contraindication to all preferred products. If so, please list the contraindications to each preferred product [documentation required]; **OR**
- C. The patient is continuing therapy with the requested non-preferred product after being stable for at least 90 days [verification in prescription claims history required] or, if not available, [verification by prescribing physician required] AND meets ONE of the following:
 1. The patient has at least 130 days of prescription claims history on file and claims history supports that the patient has received the requested non-preferred product for 90 days within a 130-day look-back period AND there is no generic equivalent available for the requested nonpreferred product (i.e. AA-rated or AB-rated to the requested nonpreferred product); **OR**
 2. When 130 days of the patient's prescription claims history file is unavailable for verification, the prescriber must verify that the patient has been receiving the requested non-preferred product for 90 days AND that the patient has been receiving the requested non-preferred product via paid claims (i.e. the patient has NOT been receiving samples or coupons or other types of waivers in order to obtain access to the requested non-preferred product) AND there is no generic equivalent available for the requested nonpreferred product (i.e. AA-rated or AB-rated to the requested nonpreferred product).

Documentation Required: When documentation is required, the prescriber must provide written documentation supporting the trials of these other products, noted in the criteria as [documentation required]. Documentation should include chart notes, prescription claims records, and/or prescription receipts.

Approval Duration: All approvals for continuation of therapy are provided for 1 year unless noted otherwise below. In cases where the initial approval is authorized in months, 1 month is equal to 30 days.

Documentation Requirements:

The Company reserves the right to request additional documentation as part of its coverage determination process. The Company may deny reimbursement when it has determined that the drug provided or services performed were not medically necessary, investigational or experimental, not within the scope of benefits afforded to the member and/or a pattern of billing or other practice has been found to be either inappropriate or excessive. Additional documentation supporting medical necessity for the services provided must be made available upon request to the Company. Documentation requested may include patient records, test results and/or credentials of the provider ordering or performing a service. The Company also reserves the right to modify, revise, change, apply and interpret this policy at its sole discretion, and the exercise of this discretion shall be final and binding.

REFERENCES

1. AerospaTM inhalation aerosol [prescribing information]. Marlborough, MA. Acton Pharmaceuticals, Inc.; August 2013.
2. Alvesco[®] inhalation aerosol [prescribing information]. Marlborough, MA. Sunovion Pharmaceuticals Inc.; January 2013.
3. Asmanex[®] HFA inhalation aerosol [prescribing information]. Whitehouse Station, NJ. Merck & Co., Inc.; August 2015.
4. Asmanex[®] Twisthaler[®] inhalation powder [prescribing information]. Whitehouse Station, NJ. Merck & Co., Inc.; September 2014.
5. Flovent[®] Diskus[®] [prescribing information]. Research Triangle Park, NC. GlaxoSmithKline; May 2014.

Drug Policy

6. Flovent® HFA inhalation aerosol [prescribing information]. Research Triangle Park, NC. GlaxoSmithKline; December 2014.
7. Pulmicort Flexhaler® inhalation powder [prescribing information]. Wilmington, DE. Astra Zeneca; July 2010.
8. ArmonAir RespiClick® [prescribing information]. Frazer, PA: Teva Respiratory; March 2018.
9. QVAR® inhalation aerosol [prescribing information]. Frazer, PA. Teva Respiratory, LLC; May 2014.
10. Arnuity™ Ellipta® inhalation powder [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2014.
11. Brocklebank D, Wright J, Cates C on behalf of the National Health Technology Assessment Inhaler Review Group. Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering corticosteroids in asthma. *BMJ*. 2001;323:896-900.
12. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. *Chest*. 2005;127: 335-371.
13. Newell K, Hume S. Choosing the right inhaler for patients with asthma. *Nurs Stand*. 2006; 21(5):46-48.
14. Devadason, Sunalene G. Recent advances in aerosol therapy for children with asthma. *J Aerosol Med*. 2006;19(1):61-66
15. Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated 2019. Accessed on December 16, 2019. Available at: <http://www.ginasthma.org>.
16. Lieberman JA. Pharmacotherapy for eosinophilic esophagitis. *Ann Allergy Asthma Immunol*. 2015;114:37-363.
17. Dellon ES, Gonsalves N, Hirano I, et al. ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). *Am J Gastroenterol*. 2013;108(5):679-92.